FDAnews
www.fdanews.com/articles/120263-ipsen-grants-license-to-debiopharm-to-develop-proprietary-cdc-251-inhibitor

Ipsen Grants License to Debiopharm to Develop Proprietary CDC-251 Inhibitor

September 8, 2009
Pharmaceutical company Ipsen Promesses said Swiss-based Debiopharm Group has been granted an exclusive worldwide license to develop and commercialize its first-in-class inhibitor of the CDC25 phosphatase enzyme, now Debio 0931, for treating various human cancers.
RTTNews